These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 28850308)

  • 1. A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study.
    Amalraj A; Varma K; Jacob J; Divya C; Kunnumakkara AB; Stohs SJ; Gopi S
    J Med Food; 2017 Oct; 20(10):1022-1030. PubMed ID: 28850308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bioavailable hydrogenated curcuminoids formulation (CuroWhite™) improves symptoms and diagnostic indicators in rheumatoid arthritis patients - A randomized, double blind and placebo controlled study.
    Jacob J; Amalraj A; Raj KKJ; Divya C; Kunnumakkara AB; Gopi S
    J Tradit Complement Med; 2019 Oct; 9(4):346-352. PubMed ID: 31453131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of curcumin nanomicelle on the clinical symptoms of patients with rheumatoid arthritis: A randomized, double-blind, controlled trial.
    Javadi M; Khadem Haghighian H; Goodarzy S; Abbasi M; Nassiri-Asl M
    Int J Rheum Dis; 2019 Oct; 22(10):1857-1862. PubMed ID: 31482684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Use of Curcumin for the Treatment of Rheumatoid Arthritis: A Systematic Review of Clinical Trials.
    Bagherniya M; Darand M; Askari G; Guest PC; Sathyapalan T; Sahebkar A
    Adv Exp Med Biol; 2021; 1291():251-263. PubMed ID: 34331695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial.
    Bickham K; Kivitz AJ; Mehta A; Frontera N; Shah S; Stryszak P; Popmihajlov Z; Peloso PM
    BMC Musculoskelet Disord; 2016 Aug; 17():331. PubMed ID: 27502582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
    Lü LJ; Teng JL; Bao CD; Han XH; Sun LY; Xu JH; Li XF; Wu HX
    Chin Med J (Engl); 2008 Apr; 121(7):615-9. PubMed ID: 18466681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran.
    Ghoryani M; Shariati-Sarabi Z; Tavakkol-Afshari J; Ghasemi A; Poursamimi J; Mohammadi M
    Biomed Pharmacother; 2019 Jan; 109():1834-1840. PubMed ID: 30551438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of conjugated linoleic acids, vitamin E and their combination on the clinical outcome of Iranian adults with active rheumatoid arthritis.
    Aryaeian N; Shahram F; Djalali M; Eshragian MR; Djazayeri A; Sarrafnejad A; Salimzadeh A; Naderi N; Maryam C
    Int J Rheum Dis; 2009 Apr; 12(1):20-8. PubMed ID: 20374312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial.
    Mandel DR; Eichas K; Holmes J
    BMC Complement Altern Med; 2010 Jan; 10():1. PubMed ID: 20067641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.
    Genovese MC; Van den Bosch F; Roberson SA; Bojin S; Biagini IM; Ryan P; Sloan-Lancaster J
    Arthritis Rheum; 2010 Apr; 62(4):929-39. PubMed ID: 20131262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the Effect of Oral N-acetylcysteine as an Adjuvant Treatment on Clinical Outcomes of Patients with Rheumatoid Arthritis: A Randomized, Double Blind Clinical Trial.
    Batooei M; Tahamoli-Roudsari A; Basiri Z; Yasrebifar F; Shahdoust M; Eshraghi A; Mehrpooya M; Ataei S
    Rev Recent Clin Trials; 2018; 13(2):132-138. PubMed ID: 29521247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
    Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
    Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis.
    Panahi Y; Hosseini MS; Khalili N; Naimi E; Majeed M; Sahebkar A
    Clin Nutr; 2015 Dec; 34(6):1101-8. PubMed ID: 25618800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial.
    Ormseth MJ; Oeser AM; Cunningham A; Bian A; Shintani A; Solus J; Tanner S; Stein CM
    Arthritis Res Ther; 2013; 15(5):R110. PubMed ID: 24020899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis.
    Fleischmann RM; Damjanov NS; Kivitz AJ; Legedza A; Hoock T; Kinnman N
    Arthritis Rheumatol; 2015 Feb; 67(2):334-43. PubMed ID: 25385260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.
    Bresnihan B; Alvaro-Gracia JM; Cobby M; Doherty M; Domljan Z; Emery P; Nuki G; Pavelka K; Rau R; Rozman B; Watt I; Williams B; Aitchison R; McCabe D; Musikic P
    Arthritis Rheum; 1998 Dec; 41(12):2196-204. PubMed ID: 9870876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.